Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Curr Med Sci. 2021 Feb;41(1):24-30. doi: 10.1007/s11596-021-2313-6. Epub 2021 Feb 13.
The role of corticosteroids in the treatment of Coronavirus disease 2019 (COVID-19) is controversial. In the present study, we evaluated the effects of adjuvant corticosteroids treatment on the outcome of patients with COVID-19 (n=966), using Propensity Score Matching to adjust for potential differences between the corticosteroids group (n=289) and the non-corticosteroids group (n=677). Analysis of data without adjusting differences in baseline characteristics indicated that the proportion of mechanical ventilation and the mortality was higher in the corticosteroids treatment group in total or severe/critical patients. The duration of viral shedding was longer in the non-corticosteroids treatment group in total or general/mild patients. After adjusting the difference between the corticosteroids and non-corticosteroids treatment group, the analysis revealed that the use of corticosteroids had no effect on the duration of viral shedding, in-hospital mortality or 28-day mortality.
皮质类固醇在 2019 冠状病毒病（COVID-19）治疗中的作用存在争议。在本研究中，我们使用倾向评分匹配来调整皮质类固醇组（n=289）和非皮质类固醇组（n=677）之间的潜在差异，评估辅助皮质类固醇治疗对 COVID-19 患者结局的影响（n=966）。数据分析未调整基线特征差异表明，皮质类固醇治疗组的机械通气比例和总死亡率或重症/危重症患者死亡率更高。在总患者或普通/轻症患者中，非皮质类固醇治疗组的病毒脱落持续时间更长。在调整皮质类固醇和非皮质类固醇治疗组之间的差异后，分析表明皮质类固醇的使用对病毒脱落持续时间、住院死亡率或 28 天死亡率没有影响。
